Unknown

Dataset Information

0

Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.

ABSTRACT: We evaluated the effectiveness of rhamnogalacturonan II (RG-II)-stimulated bone marrow-derived dendritic cells (BMDCs) vaccination on the induction of antitumor immunity in a mouse lymphoma model using EG7-lymphoma cells expressing ovalbumin (OVA). BMDCs treated with RG-II had an activated phenotype. RG-II induced interleukin (IL)-12, IL-1?, tumor necrosis factor-? (TNF-?) and interferon-? (IFN-?) production during dendritic cell (DC) maturation. BMDCs stimulated with RG-II facilitate the proliferation of CD8+ T cells. Using BMDCs from the mice deficient in Toll-like receptors (TLRs), we revealed that RG-II activity is dependent on TLR4. RG-II showed a preventive effect of immunization with OVA-pulsed BMDCs against EG7 lymphoma. These results suggested that RG-II expedites the DC-based immune response through the TLR4 signaling pathway.

SUBMITTER: Park SN 

PROVIDER: S-EPMC3584663 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.

Park Sung Nam SN   Noh Kyung Tae KT   Jeong Young-Il YI   Jung In Duk ID   Kang Hyun Kyu HK   Cha Gil Sun GS   Lee Su Jung SJ   Seo Jong Keun JK   Kang Dae Hwan DH   Hwang Tae-Ho TH   Lee Eun Kyung EK   Kwon Byungsuk B   Park Yeong-Min YM  

Experimental & molecular medicine 20130208

We evaluated the effectiveness of rhamnogalacturonan II (RG-II)-stimulated bone marrow-derived dendritic cells (BMDCs) vaccination on the induction of antitumor immunity in a mouse lymphoma model using EG7-lymphoma cells expressing ovalbumin (OVA). BMDCs treated with RG-II had an activated phenotype. RG-II induced interleukin (IL)-12, IL-1β, tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) production during dendritic cell (DC) maturation. BMDCs stimulated with RG-II facilitate the prolif  ...[more]

Similar Datasets

Unknown Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.
| S-EPMC3049234 | biostudies-literature
Unknown Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.
| S-EPMC4741802 | biostudies-other
Unknown Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.
| S-EPMC4763744 | biostudies-other
Unknown Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response.
| S-EPMC6527305 | biostudies-literature
Unknown Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100.
| S-EPMC3878805 | biostudies-literature
Unknown Immunogenic tumor cell death promotes dendritic cell migration and inhibits tumor growth via enhanced T cell immunity.
| S-EPMC8102907 | biostudies-literature
Unknown Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFN?.
| S-EPMC4216740 | biostudies-literature
Unknown Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses.
| S-EPMC4938309 | biostudies-literature
Unknown 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.
| S-EPMC6097625 | biostudies-literature
Unknown A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
| S-EPMC4116471 | biostudies-literature